Sotera Health(US:SHC)2026-02-24 21:15Financial Obligations and Ratios - The company is required to maintain specified financial ratios and tests under its Combined Senior Secured Credit Facilities, which may be affected by external economic conditions [193]. - Failure to comply with covenants could result in defaults, leading to immediate repayment demands and potential foreclosure on pledged assets [194]. - The company's cash flows may not be sufficient to service its indebtedness, potentially requiring additional financing or asset sales [195]. - The company has pledged substantially all of its assets as collateral under its Combined Senior Secured Credit Facilities [194]. - The company’s ability to make payments on its credit agreements depends on the financial performance of its subsidiaries, which may be subject to various restrictions [199]. - The company’s debt agreements include covenants and conditions that may limit its operational flexibility and ability to incur additional debt [324]. - As of December 31, 2025, the company had total debt obligations of $1,419.5 million under a term loan and $750.0 million in senior secured notes [317]. - Total contractual obligations as of December 31, 2025, amounted to $5,652.5 million, with long-term debt representing $2,942.5 million [331]. Cash Flow and Financial Performance - The company reported net cash provided by operating activities of $287.2 million for the year ended December 31, 2025, compared to $224.2 million in 2024, representing a 28.1% increase [327]. - Net cash provided by operating activities increased by $63.0 million to $287.2 million for the year ended December 31, 2025, compared to $224.2 million for the prior year, driven by a $43.2 million increase in gross profit [328]. - The company reported a net increase in cash and cash equivalents of $67.6 million during the year ended December 31, 2025, compared to a decrease of $22.8 million in 2024 [327]. - Net cash used in investing activities decreased by $43.9 million to $135.1 million in the year ended December 31, 2025, primarily due to a $41.1 million decrease in capital expenditures [329]. - Net cash used in financing activities increased by $50.0 million to $100.5 million for the year ended December 31, 2025, mainly due to an $81.1 million increase in debt principal repayments [330]. - The company expects to use cash flow generated by operations to fund business growth and repay existing debt, with no outstanding borrowings on the Revolving Credit Facility as of December 31, 2025 [314]. Capital Expenditures and Investments - Capital expenditures for the year ended December 31, 2025, amounted to $138.0 million, down from $179.1 million in 2024, indicating a decrease of 23.0% [315]. - The company expects to allocate approximately $51 million of capital expenditures in 2026 for environmental facility enhancements [316]. Stock and Ownership Structure - As of February 17, 2026, the company had 886,109,800 shares of common stock available for issuance under its 2020 Omnibus Incentive Plan, which could dilute existing stockholder ownership [202]. - The company may issue additional common stock or debt securities in the future, which could adversely affect the market price of its common stock [203]. - The concentration of ownership by sponsors, who own approximately 20.0% of the outstanding common stock, may deter actions favored by other stockholders [211]. - Anti-takeover provisions in the company's governing documents could discourage or prevent favorable changes in control or management [215]. - The company does not anticipate paying any dividends on its common stock in the foreseeable future, relying on capital appreciation for stockholder returns [221]. Legal Proceedings and Contingencies - The company is involved in various legal proceedings and claims, which may have significant financial implications [352]. - The Company recorded a liability for contingencies when their occurrence is probable and estimable, with potential material losses disclosed if not probable but reasonably possible [353]. - On April 3, 2025, the Company settled approximately 97 pending EO claims in Illinois for $30.9 million [354]. - On July 23, 2025, the Company settled approximately 129 pending EO claims in Illinois for $34.0 million [354]. - The Company may incur material defense and settlement costs that could adversely affect its financial condition and results of operations [353]. - Gain contingencies are recorded when realized, and expected recoveries under insurance contracts are recorded when assured [353]. Goodwill and Tax Assets - Goodwill totaled $1,103.2 million, or 33.8% of total assets, with significant allocations to the Sterigenics segment ($658.9 million), Nordion segment ($267.8 million), and Nelson Labs segment ($176.5 million) [347]. - The company maintained a valuation allowance of $172.3 million against deferred tax assets as of December 31, 2025, primarily due to excess interest expense on long-term debt and net operating loss carryforwards [349]. Credit Ratings and Borrowing Costs - A downgrade in credit ratings could increase future borrowing costs and reduce access to capital, impacting financial strength and hedging activities [198]. - The company reduced the interest rate spread by 0.50% across term loans under the facility, resulting in an applicable interest rate margin of Adjusted Term SOFR plus 2.50% [320]. Recent Accounting Pronouncements - Recent accounting pronouncements applicable to the Company are detailed in Note 2 of the consolidated financial statements [355].